New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 21, 2013
10:15 EDTCRH, VELT, POT, CHK, SNY, DKS, MOS, AGU, GHL, AEO, TUP, HMYOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Agrium (AGU) downgraded to Neutral from Overweight at HSBC... Chesapeake (CHK) downgraded to Neutral from Positive at Susquehanna... Harmony Gold (HMY) downgraded to Sell from Neutral at UBS... Mosaic (MOS) downgraded to Underweight from Neutral at HSBC... Potash (POT) downgraded to Underweight from Overweight at HSBC... Tupperware Brands (TUP) downgraded to Market Perform from Outperform at BMO Capital... Dick's Sporting (DKS) downgraded to In-Line from Outperform at Imperial Capital... Velti (VELT) downgraded at RBC Capital... American Eagle (AEO) downgraded to Neutral from Overweight at Piper Jaffray... Sanofi (SNY) downgraded to Market Perform from Outperform at Cowen... CRH Plc. (CRH) downgraded to Outperform from Strong Buy at Raymond James... Greenhill & Co. (GHL) downgraded to Market Perform from Outperform at JMP Securities.
News For AGU;CHK;HMY;MOS;POT;TUP;DKS;VELT;AEO;SNY;CRH;GHL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
September 3, 2015
04:46 EDTCHKStocks with implied volatility movement; YHOO CHK
Subscribe for More Information
September 2, 2015
08:38 EDTTUPTupperware Brands sees Q3 trending toward high end of 4%-6% range local currency
Subscribe for More Information
06:22 EDTDKSNew Balance to enter 'athleisure' sector, Business Insider reports
New Balance is launching a new "athleisure" line and is planning to mail a catalog to more than 1M U.S. women, Business Insider reports, citing comments from Norma Delaney, head of global marketing for NB Women. The line will compete with offerings from Lululemon (LULU), Under Armour (UA), Victoria's Secret (LB) and Dick's Sporting Goods (DKS). Reference Link
September 1, 2015
16:17 EDTSNYArdelyx regains NaP2b program from Sanofi
Subscribe for More Information
09:01 EDTSNYRegeneron and Sanofi announces Praluent Phase 3 data
Regeneron (REGN) and Sanofi (SNY) announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia patients included in the ODYSSEY clinical trial program, Praluent significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol. This analysis included 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56 percent greater reduction in LDL-C compared to placebo in both arms. Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.
August 31, 2015
09:07 EDTSNYSanofi, Google Life Sciences to collaborate to improve diabetes health outcomes
Subscribe for More Information
06:35 EDTSNYAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTSNYAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
August 28, 2015
12:01 EDTCHKStocks with call strike movement; CHK SWN
Subscribe for More Information
08:01 EDTSNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTSNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
10:00 EDTTUPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:32 EDTTUPTupperware Brands upgraded to Buy from Neutral at Sidoti
Sidoti upgraded Tupperware to Buy and maintained its $64 price target based on recent share weakness and 5.6% current dividend yield.
07:07 EDTCRHCRH subsidiary to acquire C.R. Laurence Co.
Subscribe for More Information
06:15 EDTCRHCRH CEO says significant acquisitons 'unlikely' in next 12-18 months, WSJ says
Subscribe for More Information
August 26, 2015
11:01 EDTAEOAbercrombie & Fitch surges after posting surprise Q2 profit
Abercrombie & Fitch spiked in early trading after the clothing retailer posted second quarter profit and revenue that exceeded analysts' expectations. WHAT'S NEW: Abercrombie & Fitch reported Q2 earnings per share of 12c, excluding items, on revenue of $817.8M, beating analysts' consensus estimates of a loss per share of (4c) and $811.46M, respectively. Including items, EPS was (1c). Abercrombie said the quarter included a comparable sales decrease of 4% and an adverse impact from changes in foreign currency exchange rates of about 5%. For the quarter, SSS declined 7% at the Abercrombie brand and 1% at Hollister. Executive Chairman Arthur Martinez commented that the quarterly results exceeded what the retailer signaled on its first quarter earnings call and said he is confident "that we are on the right track, although we recognize that we still have much to achieve." Looking ahead, Abercrombie & Fitch sees SSS trends improving in the second half of 2015, skewed towards the fourth quarter. The company expects continued headwinds from foreign currency exchange rates, a gross margin rate approximately flat to last year and flat operating expense compared to last year. Additionally, Abercrombie said it plans to open 15 full-price stores this fiscal year, in markets including China and Japan, and will close about 60 stores in the U.S. during the year. WHAT'S NOTABLE: Abercrombie is in the midst of a massive turnaround and announced the creation of six new positions as it restructures the management of its Abercrombie brand. The move is part of an effort to organize executives by brand rather than product after announcing last year that it would move away from logos. On its earnings conference call this morning, Abercrombie executives said that the company is "not naive" about the challenges it faces, but believes it is "on the right track" to restoring the business to health. Abercrombie said a new chief executive officer will be appointed "in due time." OTHERS TO WATCH: Abercrombie & Fitch peers include Urban Outfitters (URBN), American Eagle (AEO) and Express (EXPR). PRICE ACTION: Abercrombie & Fitch is up 11.75% in morning trading to $19.30.
August 25, 2015
08:28 EDTAEOAmerican Eagle upgraded to Outperform on valuation, execution at FBR Capital
As previously reported, FBR Capital upgraded American Eagle to Outperform from Market Perform. The firm upgraded shares based on valuation, consistent execution in a declining backdrop, reduced expectations, and potential 2H upside. The firm is cautious on the environment beyond 2H 2015 but believes strong brand recognition, product execution, right-sized fleet, and international growth position it for upside in a competitive environment.
08:27 EDTAEOAmerican Eagle should be bought at current levels, says Oppenheimer
Subscribe for More Information
06:05 EDTAEOAmerican Eagle upgraded to Outperform from Market Perform at FBR Capital
Subscribe for More Information
August 24, 2015
07:15 EDTAEOAmerican Eagle risk/reward remains compelling, says Susquehanna
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use